The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trialStephen Phillips, Joanna M. Wardlaw, Richard I. Lindley et al.|The Lancet|2012Cited by 1.2k
Core outcome set for symptomatic uncomplicated gallstone diseaseKaren Innes, Katie Gillies|British journal of surgery|2022Cited by 27